Media Statements Year None20212020201920182017 Sep 23 Regeneron Welcomes World Health Organization Recommendation for Use of REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19 301.7 KB Regeneron Welcomes World Health Organization Recommendation for Use of REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19 301.7 KB May 17 Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials 164.6 KB Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials 164.6 KB Apr 9 Regeneron Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission 127.1 KB Regeneron Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission 127.1 KB Feb 1 EMA Commences Rolling Review of Regeneron’s COVID-19 Antibody Cocktail 336.8 KB EMA Commences Rolling Review of Regeneron’s COVID-19 Antibody Cocktail 336.8 KB Jan 2 Regeneron Statement on Preliminary Injunction of the Most Favored Nation Rule 124.4 KB Regeneron Statement on Preliminary Injunction of the Most Favored Nation Rule 124.4 KB
Regeneron Welcomes World Health Organization Recommendation for Use of REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19 301.7 KB
Regeneron Welcomes World Health Organization Recommendation for Use of REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19 301.7 KB
Regeneron Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission 127.1 KB
Regeneron Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission 127.1 KB